Bellicum Phamaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bellicum Phamaceuticals, Inc.
An analyst suggested the company might end up selling its technology to a large pharma player, citing AstraZeneca’s $68m buyout of LogicBio in October as a precedent.
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
Additional views from the virtual J.P. Morgan Healthcare Conference on ways the COVID-19 pandemic has affected business practices and lessons learned for the future.
Former Novartis CEO Jimenez co-founded Aditum with former NIBR president Mark Fishman; they raised $133m and are launching Tempero Bio. Also, Atea, Galecto and SQZ went public along with one more health care SPAC, Royalty Pharma upped its Vertex royalty revenues and Mirati’s FOPO raised $926.3m.
- Drug Delivery
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.